BioPharma CreditLSE:BPCR +0.63%49 Net Margin % is 98.02% as of Dec. 2025, which is 0% below its 10-year median of 98.17. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,570 Asset Management companies, BioPharma Credit ranks better than 72.93% on this metric.
The historical rank and industry rank for BioPharma Credit's Net Margin % or its related term are showing as below:
LSE:BPCR'
s Net Margin % Range Over the Past 10 Years
Min: 89.11 Med: 98.17 Max: 98.95
Current: 98.36
LSE:BPCR's Net Margin % is ranked better than 72.93% of 1570
companies
in the Asset Management industry
Industry Median: 85.22
vs LSE:BPCR: 98.36
BioPharma Credit (LSE:BPCR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioPharma Credit Net Margin % Related Terms
BioPharma Credit Net Margin % Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Net Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a Net Margin % of 98.02% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on BioPharma Credit and its competitors. This is near median its historical median of 98.17. Over the past decade, BioPharma Credit's Net Margin % has ranged from 89.11 to 98.95. According to the industry distribution chart, BioPharma Credit ranks #425 out of 1570 companies in the Asset Management industry, placing it in the top 27.1%.
Is BioPharma Credit's Net Margin % too high?
BioPharma Credit's current Net Margin % of 98.02% is near median its 10-year median of 98.17. Over the past 10 years, this metric has ranged from a low of 89.11 to a high of 98.95. The Asset Management industry median Net Margin % is 85.22. BioPharma Credit's value of 98.02% is 15% above this industry median. Based on the distribution chart, BioPharma Credit ranks #425 out of 1570 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Net Margin % compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #425 out of 1570 companies for Net Margin %. This puts BioPharma Credit in the upper half of its industry. The industry median Net Margin % is 85.22. BioPharma Credit's value of 98.02% is 15% above this benchmark. Historically, BioPharma Credit's own Net Margin % has ranged from 89.11 to 98.95 over the past decade. While the company's 10-year median is 98.17 vs. the industry median of 85.22, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for an Asset Management company?
The median Net Margin % among Asset Management companies is 85.22, based on 1,570 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current Net Margin % of 98.02% is 15% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median Net Margin % is 85.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current Net Margin % is 98.02%, which is near median its own 10-year median of 98.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current Net Margin % is 98.02%, which is near median its 10-year median of 98.17 and 15% above the Asset Management industry median of 85.22. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Net Margin % is 98.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Net Margin %: 98.02% (near median its 10-year median of 98.17)
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
Industry Position: 15% above the Asset Management median (#425 of 1570)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
